Quick Answer
ORTHOPEDIATRICS CORP reported R&D Expense of $9.10 million for fiscal year 2025.
ORTHOPEDIATRICS CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.10M | -17.5% |
| 2024 | $11.03M | +1.3% |
| 2023 | $10.89M | +28.9% |
| 2022 | $8.45M | +52.5% |
| 2021 | $5.54M | +5.1% |
| 2020 | $5.27M | -8.3% |
| 2019 | $5.75M | +21.5% |
| 2018 | $4.73M | +38.2% |
| 2017 | $3.42M | +54.0% |
| 2016 | $2.22M | +24.3% |
| 2015 | $1.79M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.33M | -9.5% | +8.1% |
| June 30, 2025 | $2.16M | -15.1% | -8.2% |
| March 31, 2025 | $2.35M | -21.6% | -8.8% |
| September 30, 2024 | $2.58M | +0.6% | +1.3% |
| June 30, 2024 | $2.54M | -14.3% | -15.2% |
| March 31, 2024 | $3.00M | +22.6% | +17.1% |
| September 30, 2023 | $2.56M | +16.1% | -13.7% |
| June 30, 2023 | $2.97M | +69.8% | +21.3% |
- ORTHOPEDIATRICS CORP showed a decrease of -17.5% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, ORTHOPEDIATRICS CORP’s r&d expense has grown by 408.8% (from $1.79 million to $9.10 million).
- The most recent figure is from ORTHOPEDIATRICS CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: